Clinical Trial: Segmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLC

U.S., July 14 -- ClinicalTrials.gov registry received information related to the study (NCT07698990) titled 'Segmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLC' on June 18.

Brief Summary: SOLID is a multicenter, open-label, randomized, controlled, phase III non-inferiority trial comparing anatomic segmentectomy with lobectomy in patients with deeply located, solid-dominant, clinical stage IA non-small cell lung cancer (NSCLC) measuring <=2 cm. Eligible participants will undergo centralized imaging review and will be randomized preoperatively in a 1:1 ratio before induction of anesthesia.

The primary endpoint is 5-year overall survival. The key supportive secondary endpoint is 5-year recurrence-free survival. The stud...